Investor Relations
Latest Financial Results
Q1 2025 Quarterly Results
Quarter Ended Mar 31, 2025
Quarter Ended Mar 31, 2025
2025 Annual Meeting of Stockholders
Quarter Ended Mar 31, 2025
For Fiscal Year Ending Dec 31, 2024
Sign up today and receive company updates straight to your inbox.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, deramiocel (CAP-1002), is an allogeneic cell therapy that is currently in Phase 3 clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s current focus is on developing exosomes capable of delivering nucleic acids as well as proteins to treat or prevent a variety of diseases.
Capricor Therapeutics, Inc.
10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
T: 858-727-1755
Equiniti Trust Company, LLC
48 Wall Street, Floor 23
New York, NY 10005
United States
https://equiniti.com/us/